New York State Common Retirement Fund Increases Stock Position in Axonics, Inc. (NASDAQ:AXNX)

New York State Common Retirement Fund boosted its position in shares of Axonics, Inc. (NASDAQ:AXNX - Free Report) by 28.3% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 158,657 shares of the company's stock after purchasing an additional 34,989 shares during the quarter. New York State Common Retirement Fund owned about 0.31% of Axonics worth $9,873,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors also recently bought and sold shares of AXNX. Exchange Traded Concepts LLC purchased a new stake in shares of Axonics during the third quarter worth $37,000. RiverPark Advisors LLC purchased a new stake in shares of Axonics during the third quarter worth $58,000. C M Bidwell & Associates Ltd. increased its position in shares of Axonics by 108.2% during the third quarter. C M Bidwell & Associates Ltd. now owns 1,270 shares of the company's stock worth $71,000 after acquiring an additional 660 shares during the period. Sentry Investment Management LLC purchased a new position in Axonics in the fourth quarter valued at $125,000. Finally, Covestor Ltd increased its holdings in Axonics by 40.8% in the third quarter. Covestor Ltd now owns 3,143 shares of the company's stock valued at $176,000 after buying an additional 911 shares during the last quarter. 99.48% of the stock is currently owned by hedge funds and other institutional investors.

Axonics Trading Up 0.4 %

Axonics stock traded up $0.24 during midday trading on Thursday, reaching $67.11. 502,650 shares of the stock traded hands, compared to its average volume of 1,220,562. The firm has a fifty day moving average price of $67.84 and a two-hundred day moving average price of $63.07. Axonics, Inc. has a fifty-two week low of $47.59 and a fifty-two week high of $69.68.

Axonics (NASDAQ:AXNX - Get Free Report) last posted its earnings results on Tuesday, April 30th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.32). The firm had revenue of $91.41 million for the quarter, compared to analyst estimates of $89.79 million. Axonics had a negative net margin of 4.12% and a negative return on equity of 2.59%. The company's revenue for the quarter was up 29.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.19) earnings per share. Sell-side analysts expect that Axonics, Inc. will post 0.32 earnings per share for the current year.

Wall Street Analysts Forecast Growth

AXNX has been the subject of several recent research reports. Royal Bank of Canada reiterated a "sector perform" rating and set a $71.00 target price on shares of Axonics in a research note on Thursday, February 29th. CL King reaffirmed a "neutral" rating on shares of Axonics in a research note on Friday, January 12th. Truist Financial reaffirmed a "hold" rating and issued a $71.00 target price (down from $73.00) on shares of Axonics in a research note on Friday, January 12th. Wells Fargo & Company reiterated an "equal weight" rating and issued a $71.00 price target (up previously from $68.00) on shares of Axonics in a report on Wednesday, January 10th. Finally, Wolfe Research lowered shares of Axonics from an "outperform" rating to a "peer perform" rating in a report on Tuesday, January 9th. Eight research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Axonics presently has a consensus rating of "Hold" and an average target price of $70.73.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.